Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
The Journal of Obstetrics and Gynecology of India
Published in: The Journal of Obstetrics and Gynecology of India 4/2018

01-08-2018 | Invited Review Article

Ovulation Induction for the General Gynecologist

Authors: Steven R. Lindheim, Tanya L. Glenn, Megan C. Smith, Pascal Gagneux

Published in: The Journal of Obstetrics and Gynecology of India | Issue 4/2018

Login to get access

Abstract

The practice of ovulation induction often falls to the reproductive endocrinology and infertility specialist. However, attitudes toward the evaluation and treatment of infertility has shifted among general obstetrician-gynecologists (OB-GYN). This review discusses the underlying scientific basis of anovulation and clinical guidelines regarding the use of different medications for the purpose of promoting follicular recruitment and ovulation for the general OB-GYN.
Literature
1.
Thoma ME, McLain AC, Louis JF, et al. The prevalence of infertility in the United States as estimated by the current duration approach and a traditional constructed approach. Fertil Steril. 2013;99(5):1324–1331.e1.CrossRefPubMedPubMedCentral
2.
Lindsay TJ, Vitrikas KR. Evaluation and treatment of infertility. Am Fam Physician. 2015;91(5):308–14.PubMed
3.
Amer SA, Li TC, Metwally M, et al. Randomized controlled trial comparing laparoscopic ovarian diathermy with clomiphene citrate as a first-line method of ovulation induction in women with polycystic ovary syndrome. Hum Reprod. 2009;24(1):219–25.CrossRefPubMed
4.
Eldein HN. Family physicians’ attitude and practice of infertility management at primary care—Suez Canal University, Egypt. Pan Afr Med J 2013;15:106.PubMed
5.
National Collaborating Centre for Women’s and Children’s Health (UK). Ovulation disorders. In: Fertility: Assessment and treatment for people with fertility problems. London: Royal College of Obstetricians & Gynaecologists; 2013.
6.
Mesiano S, Jones EE. Chapter 55: The female reproductive system. In: Boron WF, Boulpaep EL, editors. Medical physiology. 3rd ed. Philadelphia: Elsevier; 2017.
7.
Speroff L, Fritz M, editors. Clinical gynecologic endocrinology and infertility. 8th ed. Philadelphia: Lippincott, WIlliams & Wilkins; 2011.
8.
Bao B, Garverick HA. Expression of steroidogenic enzyme and gonadotropin receptor genes in bovine follicles during ovarian follicular waves: a review. J Anim Sci. 1998;76(7):1903–21.CrossRefPubMed
9.
Roy SK, Treacy BJ. Isolation and long-term culture of human preantral follicles**Supported by grant HD 18165 (to S.K.R.) from the national institutes of health, Bethesda, Maryland. Fertil Steril. 1993;59(4):783–90.CrossRefPubMed
10.
Martinez AM, Lindheim SR. Induction of ovulation. In: Falcone T, Hurd WW, editors. Clinical reproductive medicine and surgery: a practical guide. 2nd ed. London: Springer; 2013.
11.
Brown JB. Pituitary control of ovarian function–concepts derived from gonadotrophin therapy. Aust N Z J Obstet Gynaecol. 1978;18(1):46–54.CrossRefPubMed
12.
Niswender GD, Juengel JL, Silva PJ, et al. Mechanisms controlling the function and life span of the corpus luteum. Physiol Rev. 2000;80(1):1–29.CrossRefPubMed
13.
Deveci CD, Demir B, Sengul O, et al. Clomiphene citrate ‘stair-step’ protocol vs. traditional protocol in patients with polycystic ovary syndrome: a randomized controlled trial. Arch Gynecol Obstet. 2015;291(1):179–84.CrossRefPubMed
14.
Dong X, Zheng Y, Liao X, et al. Does progesterone-induced endometrial withdrawal bleed before ovulation induction have negative effects on IUI outcomes in patients with polycystic ovary syndrome? Int J Clin Exp Pathol. 2013;6(6):1157–63.PubMedPubMedCentral
15.
Moy I, Ekpo G. Clomiphene citrate use for ovulation induction: When, why, and how? Contemporary OB/GYN 2011.
16.
Jones T, Gualtieri M, Bruno-Gaston J, et al. Evaluation of clomiphene citrate stair-step protocol for ovulation induction. Fertil Steril. 2014;102(3):e138.CrossRef
17.
Diamond MP, Kruger M, Santoro N, et al. Endometrial shedding effect on conception and live birth in women with polycystic ovary syndrome. Obstet Gynecol. 2012;119(5):902–8.CrossRefPubMedPubMedCentral
18.
Athaullah N, Proctor M, Johnson NP. Oral versus injectable ovulation induction agents for unexplained subfertility. Cochrane Database Syst Rev. 2002;3:CD003052.
19.
Sallam HN, Abdel-Bak M, Sallam NH. Does ovulation induction increase the risk of gynecological cancer? Facts Views Vis Obgyn. 2013;5(4):265–73.PubMedPubMedCentral
20.
Seyedoshohadaei F, Zandvakily F, Shahgeibi S. Comparison of the effectiveness of clomiphene citrate, tamoxifen and letrozole in ovulation induction in infertility due to isolated unovulation. Iran J Reprod Med. 2012;10(6):531–6.PubMedPubMedCentral
21.
Legro RS, Brzyski RG, Diamond MP, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med. 2014;371(2):119–29.CrossRefPubMedPubMedCentral
22.
Zakherah MS, Nasr A, El Saman AM, et al. Clomiphene citrate plus tamoxifen versus laparoscopic ovarian drilling in women with clomiphene-resistant polycystic ovary syndrome. Int J Gynaecol Obstet. 2010;108(3):240–3.CrossRefPubMed
23.
de Paula Guedes Neto E, Savaris RF, von Eye Corleta H, et al. Prospective, randomized comparison between raloxifene and clomiphene citrate for ovulation induction in polycystic ovary syndrome. Fertil Steril. 2011;96(3):769–73.CrossRefPubMed
24.
Dhaliwal LK, Suri V, Gupta KR, et al. Tamoxifen: an alternative to clomiphene in women with polycystic ovary syndrome. J Hum Reprod Sci. 2011;4(2):76–9.CrossRefPubMedPubMedCentral
25.
El-Gharib MN, Mahfouz AE, Farahat MA. Comparison of letrozole versus tamoxifen effects in clomiphen citrate resistant women with polycystic ovarian syndrome. J Reprod Infertil. 2015;16(1):30–5.PubMedPubMedCentral
26.
27.
Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16(1):25–35.CrossRefPubMed
28.
Roque M, Tostes AC, Valle M, et al. Letrozole versus clomiphene citrate in polycystic ovary syndrome: systematic review and meta-analysis. Gynecol Endocrinol. 2015;31(12):917–21.CrossRefPubMed
29.
Penzias A, Bendikson K, Butts S, et al. Role of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): A guideline. Fertil Steril. 2017;108(3):426–41.CrossRef
30.
Tock L, Carneiro G, Pereira AZ, et al. Adrenocortical production is associated with higher levels of luteinizing hormone in nonobese women with polycystic ovary syndrome. Int J Endocrinol. 2014;2014:620605.CrossRefPubMedPubMedCentral
31.
Morin-Papunen L, Rantala AS, Unkila-Kallio L, et al. Metformin improves pregnancy and live-birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double-blind, placebo-controlled randomized trial. J Clin Endocrinol Metab. 2012;97(5):1492–500.CrossRefPubMed
32.
33.
Sohrabvand F, Ansari S, Bagheri M. Efficacy of combined metformin-letrozole in comparison with metformin-clomiphene citrate in clomiphene-resistant infertile women with polycystic ovarian disease. Hum Reprod. 2006;21(6):1432–5.CrossRefPubMed
34.
Melo AS, Ferriani RA, Navarro PA. Treatment of infertility in women with polycystic ovary syndrome: approach to clinical practice. Clinics (Sao Paulo). 2015;70(11):765–9.CrossRef
35.
Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Hum Reprod. 2008;23(3):462–77.CrossRef
36.
37.
Practice Committee of American Society for Reproductive Medicine. Use of exogenous gonadotropins in anovulatory women: a technical bulletin. Fertil Steril. 2008;90(5 Suppl):S7–12.
38.
39.
Kawwass JF, Loucks TL, Berga SL. An algorithm for treatment of infertile women with polycystic ovary syndrome. Middle East Fertil Soc J. 2010;15(4):231–9.CrossRef
40.
Palshetkar N, Roongta N. Protocols for ovulation induction. In: Mumbai Obstetric and Gynecological Society; 2011.
41.
Fauser BC, Van Heusden AM. Manipulation of human ovarian function: physiological concepts and clinical consequences. Endocr Rev. 1997;18(1):71–106.PubMed
42.
Tarlatzis BC, Fauser BC, Kolibianakis EM, et al. GnRH antagonists in ovarian stimulation for IVF. Hum Reprod Update. 2006;12(4):333–40.CrossRefPubMed
43.
Birch Petersen K, Pedersen NG, Pedersen AT, et al. Mono-ovulation in women with polycystic ovary syndrome: a clinical review on ovulation induction. Reprod Biomed Online. 2016;32(6):563–83.CrossRefPubMed
44.
Casper RF, Mitwally MF. Use of the aromatase inhibitor letrozole for ovulation induction in women with polycystic ovarian syndrome. Clin Obstet Gynecol. 2011;54(4):685–95.CrossRefPubMed
45.
Lee Y, Kim Y, Chang J, et al. Changes in oral mucosal MUCI expression and salivary hormones throughout the menstrual cycle. Oral Disease. 2015;21(962):968.
46.
Fiedler K, Ezcurra D. Predicting and preventing ovarian hyperstimulation syndrome (OHSS): the need for individualized not standardized treatment. Reprod Biol Endocrinol. 2012;10(1):32.CrossRefPubMedPubMedCentral
47.
Al-Inany H, Youssef MA, Ayeleke RO, et al. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2016;4:CD001750.PubMed
48.
Practice Committee of the American Society for Reproductive Medicine. Fertility drugs and cancer: a guideline. Fertil Steril. 2016;106(7):1617–26.CrossRef
49.
Rizzuto I, Behrens RF, Smith LA. Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility. Cochrane Database Syst Rev. 2013;8:CD008215.
50.
Fernandez H, Morin-Surruca M, Torre A, et al. Ovarian drilling for surgical treatment of polycystic ovarian syndrome: a comprehensive review. Reprod Biomed Online. 2011;22(6):556–68.CrossRefPubMed
51.
Farquhar C, Brown J, Marjoribanks J, Vandekerckhove P. Laparoscopic drilling by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome. Cochrane Database Syst Rev. 2012;6:CD001122.
52.
Practice Committee of the American Society for Reproductive Medicine. Use of clomiphene citrate in infertile women: a committee opinion. Fertil Steril. 2013;100(2):341–8.CrossRef
53.
Fortune JE. Ovarian follicular growth and development in mammals. Biol Reprod. 1994;50(2):225–32.CrossRefPubMed
54.
Chizen DR, Pierson R. Transvaginal ultrasonography and female infertility. In: The Global Library of Women’s Medicine; 2010.
55.
Su H, Yi Y, Wei T, et al. Detection of ovulation, a review of currently available methods. Bioeng Transl Med. 2017;2(3):238–46.PubMedPubMedCentral
56.
Tourville TW, Shultz SJ, Vacek PM, et al. Evaluation of an algorithm to predict menstrual-cycle phase at the time of injury. J Athl Train. 2016;51(1):47–56.CrossRefPubMedPubMedCentral
57.
Hassan A, Shehata N, Wahba A. Cost effectiveness of letrozole and purified urinary FSH in treating women with clomiphene citrate-resistant polycystic ovarian syndrome: a randomized controlled trial. Hum Fertil (Camb). 2017;20(1):37–42.CrossRef
58.
59.
Kamath MS, Maheshwari A, Bhattacharya S, Lor KY, Gibreel A. Oral medications including clomiphene citrate or aromatase inhibitors with gonadotropins for controlled ovarian stimulation in women undergoing in vitro fertilisation. Cochrane Database Syst Rev. 2017;1:CD008528.
60.
61.
Suginami H, Kitagawa H, Nakahashi N, et al. A clomiphene citrate and tamoxifen citrate combination therapy: a novel therapy for ovulation induction. Fertil Steril. 1993;59(5):976–9.CrossRefPubMed
62.
Franik S, Kremer J, Nelen W, Farquhar C. Aromatase inhibitors for subfertile women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2014;24(2):CD010287.
63.
64.
Fabian CJ. The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer. Int J Clin Pract. 2007;61(12):2051–63.CrossRefPubMedPubMedCentral
65.
He Q, Liang L, Zhang C, et al. Effects of different doses of letrozole on the incidence of early-onset ovarian hyperstimulation syndrome after oocyte retrieval. Syst Biol Reprod Med. 2014;60(6):355–60.CrossRefPubMed
66.
Misso ML, Costello MF, Garrubba M, et al. Metformin versus clomiphene citrate for infertility in non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2013;19(1):2–11.CrossRefPubMed
67.
68.
Barbieri RL. Clomiphene versus metformin for ovulation induction in polycystic ovary syndrome: the winner is. J Clin Endocrinol Metab. 2007;92(9):3399–401.CrossRefPubMed
69.
Cedrin-Durnerin I, Massin N, Galey-Fontaine J, et al. Timing of FSH administration for ovarian stimulation in normo-ovulatory women: comparison of an early or a mid follicular phase initiation of a short-term treatment. Hum Reprod. 2006;21(11):2941–7.CrossRefPubMed
70.
Metadata
Title
Ovulation Induction for the General Gynecologist
Authors
Steven R. Lindheim
Tanya L. Glenn
Megan C. Smith
Pascal Gagneux
Publication date
01-08-2018
Publisher
Springer India
Published in
The Journal of Obstetrics and Gynecology of India / Issue 4/2018
Print ISSN: 0971-9202
Electronic ISSN: 0975-6434
DOI
https://doi.org/10.1007/s13224-018-1130-8

Other articles of this Issue 4/2018

The Journal of Obstetrics and Gynecology of India 4/2018 Go to the issue

Original Article

Association of Thyroid Dysfunction and Autoimmunity in Pregnant Women with Diabetes Mellitus

Case Report

Chronic Uterine Inversion Following Mid-Trimester Abortion

Editorial

Rejection Blues: Why Do Research Papers Get Rejected?

Original Article

Outcomes of Multifetal Reduction: A Hospital-Based Study

Short Commentary

Artificial Intelligence: The Future of Obstetrics and Gynecology

Original Article

Role of Platelet Distribution Width (PDW) and Plateletcrit in the Assessment of Nonthrombocytopenic Preeclampsia and Eclampsia